EP1664329A1 - Verfahren zur identifizierung präbiotisch wirksamer substanzen - Google Patents
Verfahren zur identifizierung präbiotisch wirksamer substanzenInfo
- Publication number
- EP1664329A1 EP1664329A1 EP04765537A EP04765537A EP1664329A1 EP 1664329 A1 EP1664329 A1 EP 1664329A1 EP 04765537 A EP04765537 A EP 04765537A EP 04765537 A EP04765537 A EP 04765537A EP 1664329 A1 EP1664329 A1 EP 1664329A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sample
- microorganism
- examined
- microorganisms
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000000126 substance Substances 0.000 title claims abstract description 44
- 230000000694 effects Effects 0.000 title claims abstract description 32
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 244000005700 microbiome Species 0.000 claims description 73
- 239000000523 sample Substances 0.000 claims description 53
- 244000052616 bacterial pathogen Species 0.000 claims description 29
- 239000013543 active substance Substances 0.000 claims description 18
- 244000005706 microflora Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 230000000052 comparative effect Effects 0.000 claims description 6
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000013074 reference sample Substances 0.000 claims description 4
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000007747 plating Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000004611 spectroscopical analysis Methods 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- 239000011814 protection agent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 244000005714 skin microbiome Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 19
- 230000001717 pathogenic effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000131104 Actinobacillus sp. Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241001147825 Actinomyces sp. Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000959640 Fusobacterium sp. Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241001440871 Neisseria sp. Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241001300940 Porphyromonas sp. Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000611831 Prevotella sp. Species 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 241001147736 Staphylococcus capitis Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000191973 Staphylococcus xylosus Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000589906 Treponema sp. Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical class O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- -1 organic Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- SERHXTVXHNVDKA-UHFFFAOYSA-N pantolactone Chemical compound CC1(C)COC(=O)C1O SERHXTVXHNVDKA-UHFFFAOYSA-N 0.000 description 1
- 229940115458 pantolactone Drugs 0.000 description 1
- SIEVQTNTRMBCHO-UHFFFAOYSA-N pantolactone Natural products CC1(C)OC(=O)CC1O SIEVQTNTRMBCHO-UHFFFAOYSA-N 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
Definitions
- the present invention relates to a method for identifying prebiotically active substances, the prebiotically active substances obtainable with this method, as well as medicaments, cosmetics, foods and plant treatment compositions containing these substances.
- microorganisms which are usually also found naturally on the healthy organism and may also be necessary for the optimal functioning of the organism and possibly even for the survival of the organism. Germs in the gastrointestinal tract of humans and mammals are required, for example, to ensure that food is used effectively. The more natural microflora of the skin acts as a natural protective barrier and prevents the settlement of pathogenic microorganisms.
- microorganisms that are harmful to the skin can be microorganisms that do not naturally occur in the microflora of the healthy organism.
- inflammatory conditions of the skin can be caused by an excessive proliferation of Propionibacterium acnes, which is a bacterium that can also be found on healthy skin.
- pathogenicity In addition to pathogenicity, other factors may of course also play a role in why a microorganism is desirable or undesirable. For example, germs can also be undesirable, even though they are not pathogenic, such as germs that cause body odor.
- Anti-bacterial agents are often used to combat unwanted germs.
- Non-selectively antibacterial agents such as those used to prevent and combat acne in commercially available cosmetics, not only kill the unwanted skin germs but also the desired skin germs and thus lead to a disturbance in the biological balance of the microflora.
- prabiotic and prabiotic active compositions contain the desired microorganisms, while prabiotic active compositions allow the growth of desired ones already at the application site Promote existing germs at the expense of the growth of unwanted germs without containing the desired germs themselves.
- the object of the present invention was to provide a method which makes it possible to easily find substances which have a prebiotic effect.
- substances with a prebiotic effect can be identified in a simple manner by a method which comprises the following steps: a) Examination of a sample containing microorganisms which has been exposed to at least one substance to be tested for prebiotic activity, the sample at least before the addition of the at least one substance to be examined contains at least one microorganism to be examined for its influence by the substance to be examined, b) examination of a comparative sample which was not exposed to the at least one substance to be examined for its prebiotic activity, c) determination of differences in the appearance and / or in the number, in particular concentration, of the at least one microorganism to be examined between sample and reference sample.
- a prebiotic effect means that the growth and / or survivability of the desired germs of the microflora of a particular habitat is promoted compared to the growth and / or survivability of the undesired germs of the microflora of the habitat in question.
- This can be achieved both by the fact that the active ingredient has a beneficial effect on the growth of the desired germs, without having a direct influence on the growth of the undesirable germs, and in that the active ingredient has an inhibitory effect on the growth of the undesired germs, without any direct influence to have the growth of the desired germs.
- the active ingredient has a beneficial effect on the growth of the desired germs and at the same time has an inhibitory effect on the growth of the undesired germs.
- the habitat can be any location, in particular any location of any organ or tissue of an organism that can be colonized by microorganisms naturally or due to a disease.
- the method according to the invention can be carried out by using a sample containing microorganisms for the examination, which sample was obtained by an in vitro method, in particular by cultivation, especially by cultivation in shake flasks.
- a sample containing microorganisms for the examination which sample was obtained by an in vitro method, in particular by cultivation, especially by cultivation in shake flasks.
- direct analysis of samples that should have been taken from the affected habitat can be dispensed with.
- the microorganisms to be examined are used in an in vitro method. A large number of substances can thus be examined in a simple manner to determine whether they have an effect on a large number of microorganisms which can be examined independently of one another to have. In this way, substances that have potentially prebiotic effects can be easily identified.
- the sample containing microorganisms contains no other organism than the one to be examined for its influence by the added substance. This is achieved by specifically cultivating this organism, preferably in liquid culture (in a shake flask, in reaction vessels or in cell culture plates) or on agar plates.
- This has the advantage that the multiplication of the microorganism can be used directly as an indicator of the influence of the substance to be examined, which can be done directly optically, in particular microscopically, by plating on agar plates or by a simple technical method, such as, for example, spectrometric determination of the optical density , can be determined. A high technical and time expenditure can be dispensed with here.
- cultivation is first used to check whether a substance to be tested for its prebiotic activity has a positive effect on a desired microorganism.
- a second step it is then investigated what effect the substance found to be positive on the desired microorganism has on undesired microorganisms (or possibly on other desired microorganisms).
- a substance to be tested for its prebiotic activity has a desired, ie negative, effect on an undesired microorganism. Then it can be examined what effect the substance, which has a negative effect on the undesired microorganism, has on desired microorganisms (or possibly also on other undesired microorganisms).
- the sample containing microorganisms can also contain several organisms. It can do this for example, a collective of desired microorganisms of a certain habitat or a group of undesirable microorganisms of a certain habitat. However, this can also be a sample that was taken from a natural habitat and then cultivated, preferably in shake flasks, on agar plates or in cell culture.
- a sample that has been taken from a natural habitat that is to say an in vivo sample
- an in vivo sample can also be analyzed directly without having been cultured beforehand.
- an in vivo sample is used as a comparative sample, which comes from the same habitat and was exposed to at least one substance to be tested for its prebiotic activity.
- the comparative sample is obtained by culturing under the same conditions as culturing the sample which contains the at least one substance to be tested for its prebiotic effect, with the difference that no incubation with the at least one substance to be examined.
- a culture can be divided into two equal volumes after inoculation and one of the two cultures thus obtained can be inoculated with the at least one substance to be tested for its prebiotic effect, while the other sample serves as a reference sample.
- two media of the same size can be inoculated with the same amount of sample containing microorganisms and cultured under the same conditions, with one culture being exposed to the at least one substance to be tested for its prebiotic effect and the other not.
- incubation takes place with exactly one substance to be examined for its prebiotic effect. This has the advantage that it is immediately apparent whether this substance has an influence on the growth or survivability of the sample containing at least one microorganism of the microorganisms.
- incubation takes place with a mixture of several substances to be tested for their prebiotic effect. This method can be used in particular if it is assumed that the number of hits, ie the number of substances that can be identified as effective, will be small.
- a preliminary screening can then first be carried out in order to determine whether the mixture contains substances which have a prebiotic effect.
- an individual screening can then be used to investigate the substances to which the proven effect can be attributed.
- the at least one microorganism to be examined can be any microorganism that occurs naturally in a habitat or that is known for its pathogenic and / or undesirable activity with respect to a specific habitat.
- the sample containing microorganisms can be a sample which was taken from any habitat of any organism and then optionally cultivated in vitro, the habitat in question from which the sample was taken preferably then naturally the at least one microorganism to be examined contains or may contain due to a pathogenic change.
- the sample containing microorganisms can also contain, as the only microorganism, the at least one microorganism to be examined or, if appropriate, further microorganisms which have preferably been cultivated specifically with the at least one microorganism to be examined, preferably in vitro.
- the organism from which the sample can be taken can be a plant, an animal or a human.
- microflora from which the microorganism has been removed or the microflora sample itself can be, for example, the microflora of the The mouth, stomach or intestines of vertebrates, especially mammals, especially humans.
- the microflora sample is a sample of an organ or tissue surface, in particular a sample of the leaf surface of plants, the scales or the skin, in particular of vertebrates and mammals.
- the sample containing microorganisms is a microflora sample that was taken from human skin.
- skin is preferably the skin itself, in particular the human skin, but also also the mucous membrane and skin appendages, provided that they comprise living cells, in particular hair follicles, hair roots, hair bulbs, the ventral epithelium of the nail bed (lectulus) and sebaceous glands and Understand sweat glands.
- skin here in particular also includes the skin or mucous membrane of the mouth, throat and pharynx, the esophagus, the stomach, the intestine and the rectum.
- Desired skin germs on the facial skin of humans which could be promoted in their growth by a prabiotic active substance, are, for example, coagulase-negative staphylococci, in particular S. epidermidis, S. hominis, S. warn, S. saprophyticus, S. xylosus, S. capitis or S. simulans.
- Unwanted skin germs on the facial skin of humans, which could be inhibited in their growth by a prebiotic active substance are, for example, coagulase-positive staphylococci, in particular S. aureus, or germs selected from the group consisting of Propionibacterium acnes, Candida albicans, Malassezia furfur or Corynebacterium spp.
- Undesirable germs of the oral mucosa are selected for example from Streptococcus sp., In particular S. mutans, S. salivarius, S. gordonii, S. mitis, S. oralis, S. sang ⁇ is or S.
- sobrinus from Actinomyces sp., In particular Actinomyces naesiundii, Actinobacillus sp., Especially Actinobacillus actinomycetemcomitans, Prevotella sp., in particular Prevotella intermedia, Porphyromonas sp., in particular Porphyromonas gingivalis, Treponema sp., in particular Treponema denticola, Neisseria sp., Fusobacterium sp., in particular Fusobacterium nucleatum, Candida, in particular Candida albicans or Candida glabrata.
- the analysis of the effect of the at least one substance to be tested for its prebiotic activity can be carried out in addition to the spectrometry, microscopy and plating methods, for example also by methods such as FISH, DGGE, TGGE (Electrophoresis (1989) 10 (5-6), 377- 89), RT-PCR (Real time-PCR) (Genome Res. (1996) 6 (10), 986-94), DNA microarrays (Applied and Environmental Microbiology (2001) 67 (8), 3677-82) or Antibody assays, in particular ELISA, are carried out.
- FISH Fluorescence in situ hybridization
- microorganism species, species or groups can be identified directly in the sample in a highly specific manner and, if necessary, also visualized or quantified. In this way, a distortion-free representation of the actual in situ conditions of the biocenosis possible. Even microorganisms that have not yet been cultivated and therefore not described can be identified.
- probes penetrate the cells present in the sample under investigation. If a microorganism of the type, genus or group for which the probes were developed is present in the sample under investigation, the probes in the microorganism cell bind to their target sequence and the cells can be detected on the basis of the labeling of the probes.
- DGGE stands for "denaturing gradient gel electrophoresis". It is a separation process that takes advantage of the difference in melting behavior of different double-stranded DNA fragments. This method was originally developed to detect point mutations by gel electrophoresis, so that resolution is a very sensitive method (Fisher and Lerman (1979) Cell 16, 191-200; Myers et al. (1987) Methods in Enzymology 212, 71 -104). Recently, DGGE has been used very frequently to study natural habitats (Muyzer et al. (1996) Molecular Microbial Ecology Manual 3.4.4: 1-23: Eds: Akkermans et al., Holland 1996; Diez et al. (2001) Appl Environ. Microbiol. 67 (7), 2942-2951).
- TGGE stands for "temperature gradient gel electrophoresis". In contrast to the DGGE, a temperature gradient is used instead of a denaturing agent. The methods are otherwise equivalent.
- the present invention furthermore relates to prebiotically active substances which can be obtained with the aid of a process according to the invention, the use of these prebiotically active substances and medicaments, cosmetics, foods and crop protection agents containing these prabiotically active substances.
- the present invention furthermore relates to the use of a prebiotically active substance according to the invention for the production of a Medicament to promote the growth of undesirable germs and / or to inhibit the growth of undesirable germs.
- the medicaments and cosmetics according to the invention are those for topical application. These may accordingly contain further components as are customary for such agents, in particular selected from the group consisting of vitamins, provitamins or vitamin precursors of the vitamin B group or their derivatives and derivatives of 2-furanone, panthenol, pantolactone, nicotinamide and biotin, plant extracts , MMP-1 inhibiting substances, esters of retinol (vitamin A- ⁇ ) with a C 2 -i 8 carboxylic acid, surface-active substances as emulsifiers or dispersants, amino acids and their zinc salts and their acid addition salts, film-forming and / or emulsion-stabilizing and / or thickening and / or adhesive polymers, fatty substances, surfactants, anti-perspirants and polyols, organic, mineral and modified mineral light protection filters, protein hydrolyzates and their derivatives, mono-, oligo- and polysaccharides as well as
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344970A DE10344970A1 (de) | 2003-09-27 | 2003-09-27 | Verfahren zur Identifizierung präbiotisch wirksamer Substanzen |
| PCT/EP2004/010679 WO2005033331A1 (de) | 2003-09-27 | 2004-09-23 | Verfahren zur identifizierung präbiotisch wirksamer substanzen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1664329A1 true EP1664329A1 (de) | 2006-06-07 |
Family
ID=34399002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04765537A Withdrawn EP1664329A1 (de) | 2003-09-27 | 2004-09-23 | Verfahren zur identifizierung präbiotisch wirksamer substanzen |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1664329A1 (de) |
| DE (1) | DE10344970A1 (de) |
| WO (1) | WO2005033331A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004032734A1 (de) * | 2004-03-18 | 2005-10-06 | Henkel Kgaa | Präbiotisch wirksame Substanzen für Deodorantien |
| US8815538B2 (en) | 2011-11-08 | 2014-08-26 | The Procter & Gamble Company | Method of making cosmetic compositions containing a prebiotic |
| US20130115317A1 (en) * | 2011-11-08 | 2013-05-09 | The Procter & Gamble Company | Method for Identifying Pre-Biotics and Compositions Containing the Same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2728921C3 (de) * | 1977-06-27 | 1984-07-05 | Dragoco Gerberding & Co Gmbh, 3450 Holzminden | Verwendung von Farnesol als Bakteriostatikum in Körperdesodorantien |
| DE3315058C2 (de) * | 1983-04-26 | 1985-06-13 | Dragoco Gerberding & Co Gmbh, 3450 Holzminden | Verwendung von 6-(Z)- bzw. 2-(Z)-konfigurierten 3,7,11-Trimethyl-dodeca-2,6,10-trien-1-olen als Bakteriostatikum in kosmetischen Produkten |
| DE3740186A1 (de) * | 1987-06-24 | 1989-01-05 | Beiersdorf Ag | Desodorierende und antimikrobielle zusammensetzung zur verwendung in kosmetischen oder topischen zubereitungen |
| JP2907640B2 (ja) * | 1992-06-29 | 1999-06-21 | 高砂香料工業株式会社 | 尋常性ざ瘡用皮膚外用剤 |
| FR2713086B1 (fr) * | 1993-12-02 | 1996-01-05 | Sa Sederma | Nouvelles compositions cosmétiques contenant des polyols simples. |
| FI974385A0 (fi) * | 1997-12-01 | 1997-12-01 | Xyrofin Oy | Anvaendning av xylitol foer bekaempning av jaestinfektion och xylitolpreparat foer denna anvaendning |
| DE60012610T2 (de) * | 1999-04-22 | 2005-08-04 | Shiseido Co. Ltd. | Selektive antibakterielle Zusammensetzunge |
| WO2001020020A2 (en) * | 1999-09-10 | 2001-03-22 | Cropdesign N.V. | Method to identify herbicides, fungicides or plant growth regulators |
-
2003
- 2003-09-27 DE DE10344970A patent/DE10344970A1/de not_active Ceased
-
2004
- 2004-09-23 EP EP04765537A patent/EP1664329A1/de not_active Withdrawn
- 2004-09-23 WO PCT/EP2004/010679 patent/WO2005033331A1/de not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| COATES P ET AL: "Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-Year surveillance data and snapshot distribution study", BRITISH JOURNAL OF DERMATOLOGY, vol. 146, no. 5, May 2002 (2002-05-01), pages 840 - 848, ISSN: 0007-0963 * |
| See also references of WO2005033331A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10344970A1 (de) | 2005-04-28 |
| WO2005033331A1 (de) | 2005-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al-Wathnani et al. | Bioactivity of natural compounds isolated from cyanobacteria and green algae against human pathogenic bacteria and yeast | |
| El-Diasty et al. | Antifungal activity of zinc oxide nanoparticles against dermatophytic lesions of cattle | |
| EP2041172B1 (de) | Zellulärer pyrogentest mittels toll-like rezeptor | |
| WO2001007648A1 (de) | Verfahren zum speziesspezifischen nachweis von organismen | |
| DE2946691A1 (de) | Verfahren und vorrichtung zur identifizierung von mikroorganismen | |
| Qiu et al. | Clotrimazole and econazole inhibit Streptococcus mutans biofilm and virulence in vitro | |
| WO2002095066A2 (de) | Nachweis und differenzierung von mikroorganismen der spezies yersinia pestis/yersinia pseudotuberculosis | |
| EP2279264A1 (de) | Verfahren zur charakterisierung der biologischen aktivität von helminth-eiern, nämlich von trichuris eiern | |
| EP1664329A1 (de) | Verfahren zur identifizierung präbiotisch wirksamer substanzen | |
| EP1078104B1 (de) | Nachweis von antibiotikumresistenzen in mikroorganismen | |
| WO2004009839A2 (de) | Obligonukleotide zum nachweis von mikroorganismen | |
| KR102408301B1 (ko) | 항균 활성을 갖는 신균주 스트렙토마이세스 sbc-4 및 이의 용도 | |
| DE60025906T2 (de) | Nachweis und quantifizierung von microorganismen anhand amplifizierung und restriktionsenzymeanalyse | |
| EP2276831B1 (de) | Zusammensetzung zur kultivierung von anspruchsvollen bakterien | |
| Evans et al. | Administration of doxycycline in drinking water for treatment of spiral bacterial infection in cockatiels | |
| EP1725675B1 (de) | Verfahren zur ermittlung von gegen geruchskeime wirksamen substanzen, die im axillaren bereich präbiotisch wirksam sind | |
| Preziosi et al. | Distribution of Malassezia organisms on the skin of unaffected psittacine birds and psittacine birds with feather-destructive behavior | |
| DE69632891T2 (de) | Nachweis und Identifizierung von Pilzen | |
| EP2201139B1 (de) | Nachweis von mit parodontitis assoziierten keimen | |
| DE19505056C1 (de) | In vitro Kultivierung von pleomorphen Trypanosomenstämmen | |
| Abu-Zaid | Antibacterial effect of green synthesis silver nanoparticles against Escherichia coli | |
| EP3940080B1 (de) | Erfindung betreffend analyse von mindestens einer chemischen verbindung durch simulation mindestens eines metabolisierungsvorganges | |
| Kohbata et al. | Filterable forms of Nocardia: a preferential site of infection in the mouse brain | |
| DE102004011822A1 (de) | Qualitätssicherungssystem zum Nachweis von Mikroorganismen | |
| DE19936875C2 (de) | Verfahren zum Nachweisen von Mikroorganismen in einer Probe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060308 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20080107 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HENKEL AG & CO. KGAA |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20131017 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20140228 |